AMG-562

N/A

Report date: 2026/03/19 16:47:03

Base Information

Drug NameAMG-562
Drug Alias NameAMG-562
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsAnti-CD3
TargetsB-lymphocyte antigen CD19T cell surface glycoprotein CD3
Therapy Area/IndicationsLymphoma, Mantle-CellLymphoma, FollicularLymphoma, Large B-Cell, Diffuse
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[4] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesAmgen Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBeOne Medicines LtdAmgen Inc
Active IndicationsN/A
Inactive IndicationsLymphoma, Mantle-CellLymphoma, FollicularLymphoma, Large B-Cell, Diffuse

Other Information

ATC CodeN/A
Related LinksN/A